Anomalous Type 17 Response to Viral Infection by CD8 <sup>+</sup> T Cells Lacking T-bet and Eomesodermin

Andrew M. Intlekofer(Memorial Sloan Kettering Cancer Center), Steven L. Reiner(Columbia University Irving Medical Center), Haina Shin(Washington University in St. Louis), Tullia Lindsten(The Wistar Institute), Scott M. Gordon(Cancer Research Institute of the Slovak Academy of Sciences), Arnob Banerjee(Johnson & Johnson (United States)), E. John Wherry(Parker Institute for Cancer Immunotherapy), Christopher A. Hunter(University of Pennsylvania), Caitlin S. DeJong(The Wistar Institute), Naofumi Takemoto(The Wistar Institute)
Science
July 17, 2008
10.1126/science.1159806
Cited by 381

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
|Science|2021|932
T cell responses in patients with COVID-19
|Nature reviews. Immunology|2020|873